Patents by Inventor Kenji Hirotani

Kenji Hirotani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for selecting individuals to be administered immune checkpoint inhibitor
    Patent number: 11371995
    Abstract: A method for selecting an individual to be a candidate for administration of an immune checkpoint inhibitor in treatment of a tumor, comprising: (1) a step of collecting a tumor tissue from the individual, (2) a step of determining the extent of B7-H3 expression in the tumor tissue collected in step (1), and (3) a step of selecting the individual as an individual to be a candidate for administration of the immune checkpoint inhibitor if the B7-H3 expression level is considered to be negative, is provided.
    Type: Grant
    Filed: December 25, 2017
    Date of Patent: June 28, 2022
    Assignees: Daiichi Sankyo Company, Limited, Kinki University
    Inventors: Kimio Yonesaka, Kazuhiko Nakagawa, Kenji Hirotani
  • METHOD FOR SELECTING INDIVIDUALS TO BE ADMINISTERED IMMUNE CHECKPOINT INHIBITOR
    Publication number: 20200173999
    Abstract: A method for selecting an individual to be a candidate for administration of an immune checkpoint inhibitor in treatment of a tumor, comprising: (1) a step of collecting a tumor tissue from the individual, (2) a step of determining the extent of B7-H3 expression in the tumor tissue collected in step (1), and (3) a step of selecting the individual as an individual to be a candidate for administration of the immune checkpoint inhibitor if the B7-H3 expression level is considered to be negative, is provided.
    Type: Application
    Filed: December 25, 2017
    Publication date: June 4, 2020
    Applicants: KINKI UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Kimio Yonesaka, Kazuhiko Nakagawa, Kenji Hirotani
  • METHOD FOR TREATING EGFR-TKI-RESISTANT NON-SMALL CELL LUNG CANCER BY ADMINISTRATION OF ANTI-HER3 ANTIBODY-DRUG CONJUGATE
    Publication number: 20200061031
    Abstract: [Problem] To provide a therapeutic agent and a therapeutic method for EGFR-TKI-resistant non-small cell lung cancer. [Solution] Provided are: a therapeutic agent that contains an anti-HER3 antibody-drug conjugate as an active ingredient, or a therapeutic method characterized by administering an anti-HER3 antibody-drug conjugate.
    Type: Application
    Filed: February 27, 2018
    Publication date: February 27, 2020
    Applicants: KINKI UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Kimio YONESAKA, Kazuhiko NAKAGAWA, Kenji HIROTANI
  • ANTI B7-H3 ANTIBODY
    Publication number: 20160368990
    Abstract: The present invention relates to an antibody having a therapeutic effect on a tumor. That is, the invention relates to an antibody which binds to B7-H3 to exhibit an antitumor activity. An object of the invention is to provide a pharmaceutical having a therapeutic effect on a tumor. By obtaining an anti-B7-H3 antibody which binds to B7-H3 to exhibit an antitumor activity, a pharmaceutical composition for treating a tumor comprising the antibody and the like are obtained.
    Type: Application
    Filed: June 20, 2016
    Publication date: December 22, 2016
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Shu Takahashi, Tatsuji Matsuoka, Kenji Murakami, Takeshi Takizawa, Kenji Hirotani, Atsushi Urano, Keisuke Fukuchi, Mitsuhiro Yazawa
  • Anti B7-H3 antibody
    Patent number: 9371395
    Abstract: An antibody exhibiting antitumor activity that binds to B7-H3, a functional fragment of the antibody, a pharmaceutical composition that includes the antibody or the functional fragment, methods for making the antibody or the functional fragment, methods for treating a tumor using the antibody or the functional fragment, and polynucleotides encoding the antibody or the functional fragment.
    Type: Grant
    Filed: April 24, 2012
    Date of Patent: June 21, 2016
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Shu Takahashi, Tatsuji Matsuoka, Kenji Murakami, Takeshi Takizawa, Kenji Hirotani, Atsushi Urano, Keisuke Fukuchi, Mitsuhiro Yazawa
  • ANTI B7-H3 ANTIBODY
    Publication number: 20130078234
    Abstract: An antibody exhibiting antitumor activity that binds to B7-H3, a functional fragment of the antibody, a pharmaceutical composition that includes the antibody or the functional fragment, methods for making the antibody or the functional fragment, methods for treating a tumor using the antibody or the functional fragment, and polynucleotides encoding the antibody or the functional fragment.
    Type: Application
    Filed: April 24, 2012
    Publication date: March 28, 2013
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Shu Takahashi, Tatsuji Matsuoka, Kenji Murakami, Takeshi Takizawa, Kenji Hirotani, Atsushi Urano, Keisuke Fukuchi, Mitsuhiro Yazawa